NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse--a microtubule-deficient model of schizophrenia

Peptides. 2010 Jul;31(7):1368-73. doi: 10.1016/j.peptides.2010.04.011. Epub 2010 Apr 22.


NAP (generic name, davunetide) is an active fragment of activity-dependent neuroprotective protein (ADNP). ADNP-/- embryos exhibit CNS dysgenesis and die in utero. ADNP+/- mice survive but demonstrate cognitive dysfunction coupled with microtubule pathology. NAP treatment ameliorates, in part, ADNP-associated dysfunctions. The microtubule, stable tubule-only polypeptide (STOP) knockout mice were shown to provide a reliable model for schizophrenia. Here, STOP-/- as well as STOP+/- showed schizophrenia-like symptoms (hyperactivity) that were ameliorated by chronic treatment with the antipsychotic drug, clozapine. Daily intranasal NAP treatment significantly decreased hyperactivity in the STOP+/- mice and protected visual memory.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Behavior, Animal / drug effects*
  • Cognition Disorders / drug therapy*
  • Cognition Disorders / genetics
  • Cognition Disorders / metabolism
  • Disease Models, Animal
  • Homeodomain Proteins / genetics
  • Homeodomain Proteins / metabolism
  • Mice
  • Mice, Inbred BALB C
  • Mice, Transgenic
  • Microtubule-Associated Proteins / genetics*
  • Microtubule-Associated Proteins / metabolism
  • Nerve Tissue Proteins / genetics
  • Nerve Tissue Proteins / metabolism
  • Oligopeptides / therapeutic use*
  • Schizophrenia / drug therapy*
  • Schizophrenia / genetics
  • Schizophrenia / metabolism


  • Adnp protein, mouse
  • Homeodomain Proteins
  • Microtubule-Associated Proteins
  • Mtap6 protein, mouse
  • Nerve Tissue Proteins
  • Oligopeptides
  • davunetide